Skip to Main Content

Hello, everyone, and welcome to another working week. The weekend respite went quickly, did it not? Well, we hope it was invigorating and refreshing, because the oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? So grab a cup of stimulation — our choice remains apple cider donut for those keeping track — and dig in for another busy day. On that note, here are some tidbits. Hope you conquer the world and, as always, do keep in touch …

AstraZeneca (AZN) acknowledged an early study supporting a cancer drug was falsified, The Telegraph says. Two years ago, the drug maker paid Acerta Pharma $4 billion on the strength of a novel drug being developed to treat blood cancers and solid tumors. But last month, Acerta retracted an ­abstract published four months before the deal purportedly showing its drug was effective in treating solid tumors in mice. The company says the episode did not impact the integrity of overall trial data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!